Dupilumab in Adults With Moderate to Severe Atopic Dermatitis
Lisa A. Beck(University of Rochester Medicine), Arsalan Shabbir(Regeneron (United States)), Ryszard Galus(Medical University of Warsaw), Mette Deleuran(Aarhus University Hospital), Robert Bissonnette(Innovaderm (Canada)), Anna Coleman(Central Michigan University), Christine Xu(Sanofi (United States)), Elena Avetisova(Regeneron (United States)), Jing Xiao(Dalian Medical University), Takeshi Nakahara(Kyushu University), Robert Dingman(Regeneron (United States)), Guy Gherardi(Sanofi (United Kingdom)), Ariane Dubost-Brama(Galderma (France))
Cited by 64
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k
Cytokine modulation of atopic dermatitis filaggrin skin expression
|Journal of Allergy and Clinical Immunology|2007|1.1k